Literature DB >> 32312833

The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.

Wenhui Chu1, Xi Zhang1, Lihua Qi1, Yenan Fu1, Peng Wang1, Wei Zhao1, Juan Du1, Jing Zhang1, Jun Zhan1, Yunling Wang1, Wei-Guo Zhu2, Yu Yu3, Hongquan Zhang3.   

Abstract

Aberrant activation of histone methyltransferase EZH2 and ribosome synthesis strongly associate with cancer development and progression. We previously found that EZH2 regulates RNA polymerase III-transcribed 5S ribosomal RNA gene transcription. However, whether EZH2 regulates ribosome synthesis is still unknown. Here, we report that EZH2 promotes ribosome synthesis by targeting and silencing a long noncoding RNA PHACTR2-AS1. PHACTR2-AS1 directly bound ribosome DNA genes and recruited histone methyltransferase SUV39H1, which in turn triggered H3K9 methylation of these genes. Depletion of PHACTR2-AS1 resulted in hyperactivation of ribosome synthesis and instability of ribosomal DNA, which promoted cancer cell proliferation and metastasis. Administration of PHACTR2-AS1-30nt-RNA, which binds to SUV39H1, effectively inhibited breast cancer growth and lung metastasis in mice. PHACTR2-AS1 was downregulated in breast cancer patients, where lower PHACTR2-AS1 expression promoted breast cancer development and correlated with poor patient outcome. Taken together, we demonstrate that PHACTR2-AS1 maintains a H3K9 methylation-marked silent state of ribosomal DNA genes, comprising a regulatory axis that controls breast cancer growth and metastasis. SIGNIFICANCE: These findings reveal that EZH2 mediates ribosomal DNA stability via silencing of PHACTR2-AS1, representing a potential therapeutic target to control breast cancer growth and metastasis. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32312833     DOI: 10.1158/0008-5472.CAN-19-3326

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  The expression and potential mechanism of EGFR and EZH2 in breast cancer.

Authors:  Xiaoqi Tang; Taosheng Zhou; Jiayue Shen; Ming Luo; Huiming Yuan; Denghua Pan; Fu Li
Journal:  Gland Surg       Date:  2021-08

2.  Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus.

Authors:  Zeina Nehme; Sébastien Pasquereau; Sandy Haidar Ahmad; Ranim El Baba; Georges Herbein
Journal:  EBioMedicine       Date:  2022-05-18       Impact factor: 11.205

Review 3.  Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance.

Authors:  Amr R Elhamamsy; Brandon J Metge; Heba A Alsheikh; Lalita A Shevde; Rajeev S Samant
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

4.  Development of RNA binding proteins expression signature for prognosis prediction in gastric cancer patients.

Authors:  Liqiang Zhou; You Wu; Lin Xin; Qi Zhou; Shihao Li; Yiwu Yuan; Jinliang Wang; Dengzhong Wu
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

Review 5.  The roles of epigenetics in cancer progression and metastasis.

Authors:  Jocelyn F Chen; Qin Yan
Journal:  Biochem J       Date:  2021-09-17       Impact factor: 3.766

6.  Genetic Variation and Recurrent Haplotypes on Chromosome 6q23-25 Risk Locus in Familial Lung Cancer.

Authors:  Anthony M Musolf; Claire L Simpson; Bilal A Moiz; Claudio W Pikielny; Candace D Middlebrooks; Diptasri Mandal; Mariza de Andrade; Michael D Cole; Colette Gaba; Ping Yang; Ming You; Yafang Li; Elena Y Kupert; Marshall W Anderson; Ann G Schwartz; Susan M Pinney; Christopher I Amos; Joan E Bailey-Wilson
Journal:  Cancer Res       Date:  2021-04-14       Impact factor: 13.312

Review 7.  Progress of Breast Cancer basic research in China.

Authors:  Xuerong Wang; Chao Wang; Jiaheng Guan; Baoan Chen; Lin Xu; Ceshi Chen
Journal:  Int J Biol Sci       Date:  2021-05-11       Impact factor: 6.580

8.  Web tools to perform long non-coding RNAs analysis in oncology research.

Authors:  Shixing Gu; Guangjie Zhang; Qin Si; Jiawen Dai; Zhen Song; Yingshuang Wang
Journal:  Database (Oxford)       Date:  2021-07-23       Impact factor: 3.451

Review 9.  Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.

Authors:  Liyuan Peng; Jingwen Jiang; Bo Tang; Edouard C Nice; Yuan-Yuan Zhang; Na Xie
Journal:  Theranostics       Date:  2020-08-18       Impact factor: 11.556

10.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.